S 476
118th Congress
Senate
Health
Genetics
Medicare
Prescription drugs
Maintaining Investments in New Innovation Act
Introduced: February 16, 2023
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 16, 2023
Read twice and referred to the Committee on Finance.
Feb 16, 2023
Introduced in Senate
Plain-English summary
Maintaining Investments in New Innovation Act
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
What's happening now
Read twice and referred to the Committee on Finance.
Committees of jurisdiction
1